The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Acute Respiratory Distress Syndrome
Matthay, M. A. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605303342209 · Cited by 4,923
The Acute Respiratory Distress Syndrome
Ware, L. B., & Matthay, M. A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005043421806 · Cited by 4,666
Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.
Yang, Y., Nunes, F. A., Berencsi, K., Furth, E. E., Gönczöl, E., & Wilson, J. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.10.4407 · Cited by 1,575
Self-citationBone, R. C. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-6-457 · Cited by 1,368
Yang, Y., Li, Q., Ertl, H. C., & Wilson, J. M. (1995) · Journal of Virology · doi:10.1128/jvi.69.4.2004-2015.1995 · Cited by 1,032
Self-citationActivation of Coagulation after Administration of Tumor Necrosis Factor to Normal Subjects
van der Poll, T., Büller, H. R., ten Cate, H., Wortel, C. H., Bauer, K. A., van Deventer, S. J. H., Hack, C. E., Sauerwein, H. P., Rosenberg, R. D., & ten Cate, J. W. (1990) · New England Journal of Medicine · doi:10.1056/nejm199006073222302 · Cited by 667
Tripathy, S. K., Black, H. B., Goldwasser, E., & Leiden, J. M. (1996) · Nature Medicine · doi:10.1038/nm0596-545 · Cited by 628
Yang, Y., Ertl, H. C. J., & Wilson, J. M. (1994) · Immunity · doi:10.1016/1074-7613(94)90074-4 · Cited by 611
Self-citationInterleukin-6 in the Injured Patient: Marker of Injury or Mediator of Inflammation?
Biffl, W. L., Moore, E. E., Moore, F. A., & Peterson, V. M. (1996) · Annals of Surgery · doi:10.1097/00000658-199611000-00009 · Cited by 502
Postinjury Multiple Organ Failure: A Bimodal Phenomenon
Moore, F. A., Sauaia, A., Moore, E. E., Haenel, J. B., Burch, J. M., & Lezotte, D. C. (1996) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/00005373-199604000-00001 · Cited by 491
Research works printed but not linked: 4
- Morsy, 1993, Efficient adenoviral-mediated ornithine transcarbamylase expression in deficient mouse and human hepatocytes, J. Clin. Invest., 92, 1580, 10.1172/JCI116739 · doi:10.1172/jci116739
- Wang, 1997, Persistent transgene expression in mouse liver following in vivo gene transfer with a ΔE1/ΔE4 adenovirus vector, Gene Ther., 4, 393, 10.1038/sj.gt.3300404 · doi:10.1038/sj.gt.3300404
- Ye, 1998, Evaluating the potential of germ line transmission after intravenous administration of recombinant adenovirus in the C3H mouse, Hum. Gene Ther., 9, 2135, 10.1089/hum.1998.9.14-2135 · doi:10.1089/hum.1998.9.14-2135
- Yao, 1996, Adenovirus-mediated transfer of human factor IX gene in immunodeficient and normal mice: evidence for prolonged stability and activity of the transgene in liver, Viral Immunol., 9, 141, 10.1089/vim.1996.9.141 · doi:10.1089/vim.1996.9.141
Cited by
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Viral vector platforms within the gene therapy landscape
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00487-6 · Cited by 1,404
Self-citationGene therapy clinical trials worldwide to 2012 – an update
Ginn, S. L., Alexander, I. E., Edelstein, M. L., Abedi, M. R., & Wixon, J. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2698 · Cited by 1,159
Normothermic Ex Vivo Lung Perfusion in Clinical Lung Transplantation
Cypel, M., Yeung, J. C., Liu, M., Anraku, M., Chen, F., Karolak, W., Sato, M., Laratta, J., Azad, S., Madonik, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014597 · Cited by 1,106
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
“27,28 AAV vectors, conversely, have gained wide acceptance as in vivo gene transfer vectors due to their very mild proin fl ammatory pro fi le.”
Karikó, K., Muramatsu, H., Ludwig, J., & Weissman, D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr695 · Cited by 898
Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
“First, AAV vectors had never been administered to liver in human subjects before, and the only death in a gene therapy trial at that point had been in a trial in which adenoviral vectors were administered to the liver in subjects with OTC deficienc”
Viral and nonviral delivery systems for gene delivery
Nayerossadat, N., Maedeh, T., & Ali, P. (2012) · Advanced Biomedical Research · doi:10.4103/2277-9175.98152 · Cited by 858
Misra, S., Hascall, V. C., Markwald, R. R., & Ghatak, S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00201 · Cited by 830
Hinderer, C., Katz, N., Buza, E. L., Dyer, C., Goode, T., Bell, P., Richman, L. K., & Wilson, J. M. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.015 · Cited by 814
Self-citationLee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.04.001 · Cited by 691
Adenovirus Serotype 5 Hexon Mediates Liver Gene Transfer
Waddington, S. N., McVey, J. H., Bhella, D., Parker, A. L., Barker, K., Atoda, H., Pink, R., Buckley, S. M. K., Greig, J. A., Denby, L., et al. (2008) · Cell · doi:10.1016/j.cell.2008.01.016 · Cited by 643
DNA-based therapeutics and DNA delivery systems: A comprehensive review
Patil, S. D., Rhodes, D. G., & Burgess, D. J. (2005) · The AAPS Journal · doi:10.1208/aapsj070109 · Cited by 630
GENE THERAPY: Twenty-First Century Medicine
Verma, I. M., & Weitzman, M. D. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.050304.091637 · Cited by 616
Gene therapy clinical trials worldwide to 2007—an update
Edelstein, M. L., Abedi, M. R., & Wixon, J. (2007) · The Journal of Gene Medicine · doi:10.1002/jgm.1100 · Cited by 584
CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future
Uddin, F., Rudin, C. M., & Sen, T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01387 · Cited by 581
Adenovirus vectors for gene therapy, vaccination and cancer gene therapy
Wold, W., & Toth, K. (2014) · Current Gene Therapy · doi:10.2174/1566523213666131125095046 · Cited by 555
High, K. A., & Roncarolo, M. G. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1706910 · Cited by 555
Therapeutic in vivo delivery of gene editing agents
Raguram, A., Banskota, S., & Liu, D. R. (2022) · Cell · doi:10.1016/j.cell.2022.03.045 · Cited by 522
Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
Duan, D. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.011 · Cited by 489
Hyaluronan–CD44 interactions as potential targets for cancer therapy
Misra, S., Heldin, P., Hascall, V. C., Karamanos, N. K., Skandalis, S. S., Markwald, R. R., & Ghatak, S. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08071.x · Cited by 494
Entering the Modern Era of Gene Therapy
Anguela, X. M., & High, K. A. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-012017-043332 · Cited by 471
Lundstrom, K. (2018) · Diseases · doi:10.3390/diseases6020042 · Cited by 469
Dendrimers in Oncology: An Expanding Horizon
Tekade, R. K., Kumar, P. V., & Jain, N. K. (2009) · Chemical Reviews · doi:10.1021/cr068212n · Cited by 466
Ghosh, P. S., Kim, C.-K., Han, G., Forbes, N. S., & Rotello, V. M. (2008) · ACS Nano · doi:10.1021/nn800507t · Cited by 459
Viral Vectors for Gene Therapy: Translational and Clinical Outlook
Kotterman, M. A., Chalberg, T. W., & Schaffer, D. V. (2015) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071813-104938 · Cited by 424
E-cadherin: Its dysregulation in carcinogenesis and clinical implications
Wong, S. H. M., Fang, C. M., Chuah, L.-H., Leong, C. O., & Ngai, S. C. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.11.010 · Cited by 400
Zhu, J., Huang, X., & Yang, Y. (2007) · Journal of Virology · doi:10.1128/jvi.02192-06 · Cited by 366
Viral vectors: from virology to transgene expression
Bouard, D., Alazard‐Dany, N., & Cosset, F. (2009) · British Journal of Pharmacology · doi:10.1038/bjp.2008.349 · Cited by 360
Raper, S. E., Yudkoff, M., Chirmule, N., Gao, G.-P., Nunes, F., Haskal, Z. J., Furth, E. E., Propert, K. J., Robinson, M. B., Magosin, S., et al. (2002) · Human Gene Therapy · doi:10.1089/10430340152712719 · Cited by 354
Self-citationGene therapy clinical trials worldwide 1989–2004—an overview
Edelstein, M. L., Abedi, M. R., Wixon, J., & Edelstein, R. M. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.619 · Cited by 350
Enhancing the quality and transparency of health research
Groves, T. (2008) · BMJ · doi:10.1136/bmj.a718 · Cited by 332
Mimicking the Cell: Bio-Inspired Functions of Supramolecular Assemblies
Tu, Y., Peng, F., Adawy, A., Men, Y., Abdelmohsen, L. K. E. A., & Wilson, D. A. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00344 · Cited by 316
Viral gene therapy strategies: from basic science to clinical application
Young, L. S., Searle, P. F., Onion, D., & Mautner, V. (2006) · The Journal of Pathology · doi:10.1002/path.1896 · Cited by 313
(2013) · PubMed · Cited by 308
Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency
Wilson, J. M. (2009) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2008.12.016 · Cited by 299
Self-citationParker, A. L., Waddington, S. N., Nicol, C. G., Shayakhmetov, D. M., Buckley, S. M., Denby, L., Kemball-Cook, G., Ni, S., Lieber, A., McVey, J. H., et al. (2006) · Blood · doi:10.1182/blood-2006-04-008532 · Cited by 297
Wisse, E., Jacobs, F., Topal, B., Frederik, P., & De Geest, B. (2008) · Gene Therapy · doi:10.1038/gt.2008.60 · Cited by 289
Karikó, K., Muramatsu, H., Keller, J. M., & Weissman, D. (2012) · Molecular Therapy · doi:10.1038/mt.2012.7 · Cited by 282
Pre-existing immunity against Ad vectors: Humoral, cellular, and innate response, what's important?
Fausther-Bovendo, H., & Kobinger, G. P. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.29594 · Cited by 276
Kaufmann, K. B., Büning, H., Galy, A., Schambach, A., & Grez, M. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202287 · Cited by 276
Genotoxicity of Retroviral Integration In Hematopoietic Cells
Nienhuis, A. W., Dunbar, C. E., & Sorrentino, B. P. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.001 · Cited by 258
Non-viral Delivery of Nucleic Acids: Insight Into Mechanisms of Overcoming Intracellular Barriers
Durymanov, M., & Reineke, J. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00971 · Cited by 254
Efficient Non-Viral Ocular Gene Transfer with Compacted DNA Nanoparticles
Farjo, R., Skaggs, J., Quiambao, A. B., Cooper, M. J., & Naash, M. I. (2006) · PLoS ONE · doi:10.1371/journal.pone.0000038 · Cited by 208
“Additionally, concerns regarding the safety of using viral vectors in human patients have been raised and some trials have resulted in oncogenesis or even mortality [22,24–26].”
BackgroundHordeaux, J., Buza, E. L., Jeffrey, B., Song, C., Jahan, T., Yuan, Y., Zhu, Y., Bell, P., Li, M., Chichester, J. A., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aba9188 · Cited by 174
Self-citationGene Therapy for Malignant Glioma: Current Clinical Status
Pulkkanen, K. J., & Yla-Herttuala, S. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.07.357 · Cited by 161
Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency
Prieve, M. G., Harvie, P., Monahan, S. D., Roy, D., Li, A. G., Blevins, T. L., Paschal, A. E., Waldheim, M., Bell, E. C., Galperin, A., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.12.024 · Cited by 145
Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing
Han, H. A., Pang, J. K. S., & Soh, B.-S. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01893-z · Cited by 134
Adeno-Associated Virus Structural Biology as a Tool in Vector Development
Drouin, L. M., & Agbandje-McKenna, M. (2013) · Future Virology · doi:10.2217/fvl.13.112 · Cited by 114
Adenoviruses as gene/vaccine delivery vectors: Promises and pitfalls
Appaiahgari, M. B., & Vrati, S. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.993374 · Cited by 110
Human artificial chromosomes for gene delivery and the development of animal models
Kazuki, Y., & Oshimura, M. (2011) · Molecular Therapy · doi:10.1038/mt.2011.136 · Cited by 108
Lee, B. H., Hwang, D. M., Palaniyar, N., Grinstein, S., Philpott, D. J., & Hu, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035812 · Cited by 102
“The patient suffered from systemic inflammatory response syndrome with pathological features of acute respiratory distress syndrome (ARDS) after receiving a high dose Ad [6].”
BackgroundMechanisms of nanoparticle-mediated siRNA transfection by melittin-derived peptides
Hou, K. K., Pan, H., Ratner, L., Schlesinger, P. H., & Wickline, S. A. (2013) · ACS Nano · doi:10.1021/nn403311c · Cited by 95
“20 induction of cancer to toxicity associated with saturation effects.(68-70) Due to the ability to”
Nanotechnology-Based Strategies to Overcome Current Barriers in Gene Delivery
Mirón-Barroso, S., Domènech, E. B., & Trigueros, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168537 · Cited by 91
Emerging patent landscape for non-viral vectors used for gene therapy
Picanço-Castro, V., Pereira, C. G., Covas, D. T., Porto, G. S., Athanassiadou, A., & Figueiredo, M. L. (2020) · Nature Biotechnology · doi:10.1038/s41587-019-0402-x · Cited by 88
Innate immunity to adenovirus: lessons from mice
Atasheva, S., Yao, J., & Shayakhmetov, D. M. (2019) · FEBS Letters · doi:10.1002/1873-3468.13696 · Cited by 87
Hordeaux, J., Lamontagne, R. J., Song, C., Buchlis, G., Dyer, C., Buza, E. L., Ramezani, A., Wielechowski, E., Greig, J. A., Chichester, J. A., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.02.002 · Cited by 81
Self-citationGene therapy for ocular diseases
Liu, M. M., Tuo, J., & Chan, C.-C. (2011) · British Journal of Ophthalmology · doi:10.1136/bjo.2009.174912 · Cited by 82
Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses
Ghoraba, H. H., Akhavanrezayat, A., Karaca, I., Yavari, N., Lajevardi, S., Hwang, J., Regenold, J., Matsumiya, W., Pham, B., Zaidi, M., et al. (2022) · Clinical Ophthalmology · doi:10.2147/opth.s364200 · Cited by 76
“Severe side effects have been reported using adenovirus, as severe as death of a patient with systemic fever and liver damage in a clinical trial for metabolic disease.(9) Although it does not usually replicate inside hosts, a replication-competent virus can be inadvertently created by combination of adenoviral derive…”
BackgroundPalazzi, X., Pardo, I. D., Sirivelu, M. P., Newman, L., Kumpf, S. W., Qian, J., Franks, T., Lopes, S., Liu, J., Monarski, L., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2021.116 · Cited by 60
“hepatic enzyme elevations and systemic inflammatory response syndromes in animals and humans, sensory neuron degeneration/necrosis in animals, and concerns regarding insertional mutagenesis in animals have been raised.(8)”
BackgroundCircumventing Antivector Immunity: Potential Use of Nonhuman Adenoviral Vectors
Lopez-Gordo, E., Podgorski, I. I., Downes, N., & Alemany, R. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.228 · Cited by 65
Chan, Y. K., Dick, A. D., Hall, S. M., Langmann, T., Scribner, C. L., Mansfield, B. C., & for the Ocular Gene Therapy Inflammation Working Group (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.4.3 · Cited by 56
Introducing Genes to the Heart: All About Delivery
Hajjar, R. J., & Ishikawa, K. (2017) · Circulation Research · doi:10.1161/circresaha.116.310039 · Cited by 36
Ocular Inflammation and Treatment Emergent Adverse Events in Retinal Gene Therapy
Mehta, N., Robbins, D. A., & Yiu, G. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000366 · Cited by 33
Adenovirus vectors deleted for genes essential for viral DNA replication
Schaack, J. (2005) · Frontiers in Bioscience · doi:10.2741/1607 · Cited by 26
Purdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
“The immune reaction seen with other viral vectors delivered systemically has sometimes been severe and even fatal in very rare cases (Raper et al., 2003).”
Adenovirus vector delivery stimulates natural killer cell recognition
Tomasec, P., Wang, E. C. Y., Groh, V., Spies, T., McSharry, B. P., Aicheler, R. J., Stanton, R. J., & Wilkinson, G. W. G. (2007) · Journal of General Virology · doi:10.1099/vir.0.82685-0 · Cited by 18
“, 2001), which have resulted in morbidity and mortality in gene therapy trials (Crystal et al., 1994; Marshall, 1999; Raper et al., 2003; Schnell et al., 2001).”
BackgroundGrandchamp, N., Altémir, D., Philippe, S., Ursulet, S., Pilet, H., Serre, M.-C., Lenain, A., Serguera, C., Mallet, J., & Sarkis, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099649 · Cited by 11
Genetic engineering in athletes
Wells, D. (2008) · BMJ · doi:10.1136/bmj.a607 · Cited by 1
Metadata
- Authors
- Raper, S. E., Chirmule, N., Lee, F. S., Wivel, N. A., Bagg, A., Gao, G.-P., Wilson, J. M., & Batshaw, M. L.
- Venue
- Molecular Genetics and Metabolism
- Publisher
- Elsevier BV
- Published
- 2003-09
- Volume
- 80
- Issue
- 1-2
- Pages
- 148-158
- ISSN
- 1096-7192 (ISSN-L)
- OpenAlex
- W2093424805
- Cited by
- 1,498
- References
- 37
- FWCI
- 33.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.